Intravitreal bevacizumab (avastin) in central retinal vein occlusion

Jason Hsu, Richard S. Kaiser, Arunan Sivalingam, Prema Abraham, Mitchell S. Fineman, Michael A. Samuel, James F. Vander, Carl D. Regillo, Allen C. Ho

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


PURPOSE: To describe the effects of intravitreal bevacizumab in eyes with macular edema resulting from central retinal vein occlusions (CRVO). METHODS: Retrospective consecutive case series of patients diagnosed with macular edema from CRVO who received intravitreal bevacizumab. RESULTS: Thirty eyes of 29 patients with an average age of 72 years (range, 54-87 years) had intravitreal bevacizumab injections. Mean follow-up was 18.1 weeks. Initial mean visual acuity was 20/394. At the 1- and 2-month follow-up, mean visual acuity improved to 20/237 (n = 26, P = 0.04) and 20/187 (n = 21, P = 0.008), respectively. At the 3- and 4-month follow-up, visual acuity improved from 20/228 to 20/157 (n = 15, P = 0.05) and from 20/313 to 20/213 (n = 11, P = 0.03), respectively. No significant changes in visual acuity were found after 4 months though the number of patients in this group was small. Duration of treatment effect following an injection appears to be limited to 2 months for most patients. No ocular or systemic adverse reactions were noted. CONCLUSIONS: The visual benefits of intravitreal bevacizumab for macular edema due to CRVO are apparent early but are not sustained without repeated injections. Larger clinical studies with long-term follow-up will be necessary to better elicit the best regimen for this therapy.

Original languageEnglish
Pages (from-to)1013-1019
Number of pages7
Issue number8
StatePublished - Oct 2007
Externally publishedYes


  • Avastin
  • Bevacizumab
  • Central retinal vein occlusion
  • Macular edema


Dive into the research topics of 'Intravitreal bevacizumab (avastin) in central retinal vein occlusion'. Together they form a unique fingerprint.

Cite this